Expression of the inhibitory Fc gamma receptor IIB ( FCGR2B, CD32B) on follicular lymphoma cells lowers the response rate to rituximab monotherapy ( SAKK 35/98).

Authors :: Lee, Chern Siang
Ashton‐Key, Margaret
Cogliatti, Sergio
Rondeau, Stephanie
Schmitz, Shu‐Fang Hsu
Ghielmini, Michele
Cragg, Mark S
Johnson, Peter
Source :: British Journal of Haematology. Jan2015, Vol. 168 Issue 1, p145-148. 4p. 1 Color Photograph, 1 Chart.
Publication Year :: 2015
Abstract: The article presents a study which reveals that Fc gamma receptor IIB decreases efficacy of rituximab monotherapy in treatment of follicular lymphoma (FL). Topics discussed include reduction in half life of antibody due to inhibitory FCGR2B, higher expression level of FCGR2B as compared to cells of FL and possible therapeutic significance of FCGR2B in lymphoid malignancies.

Subjects :: *LYMPHOMA treatment
*RITUXIMAB
*IMMUNOGLOBULINS
*CANCER cells
*LYMPHATIC diseases

Full Text Access

Tools